OX40/TNFRSF4 Antibody (7D6) [DyLight 550]

Product Discontinued

OX40/TNFRSF4 Antibody (7D6) [DyLight 550] Summary

• Immunogen: CHO-derived feline CD134-Fc fusion protein.
• Specificity: NB100-64375 recognizes feline CD134, otherwise known as OX40, a 43kDa type I membrane protein and member of the tumor necrosis factor receptor superfamily, expressed predominantly by CD4+ activated T cells, and a key regulator of T cell-dependent immune responses. CD134 has been identified as the receptor for the OX40 ligand, CD252, expressed by activated B cells, acting as a co-stimulatory signal for the stimulation and secretion of immunoglobulins. CD134 has also been identified as a binding receptor for Feline Immunodeficiency Virus (FIV), acting along with CXC chemokine receptor 4 (CXCR4) to facilitate the entry of the virus into CD4+ primary target cells.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF4
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Western Blot
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein A purified

Notes

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Alternate Names for OX40/TNFRSF4 Antibody (7D6) [DyLight 550]

• ACT-135
• ACT35 antigen
• ACT35ATC35 antigen
• CD134 antigen
• CD134
• Ly-70
• OX40 cell surface antigen
• OX40 homologue
• OX40
• OX40L receptor
• OX40lymphoid activation antigene ACT35
• TAX transcriptionally-activated glycoprotein 1 receptor
• tax-transcriptionally activated glycoprotein 1 receptor
• TNFRSF4
• tumor necrosis factor receptor superfamily member 4
• tumor necrosis factor receptor superfamily, member 4
• Txgp1
• TXGP1L
• TXGP1LOX40 antigen

Background

The OX40 receptor is also known as CD134, ACT35, and tumor necrosis factor receptor superfamily member 4. This receptor is expressed on activated CD4+ and CD8+ T cells and B cells. The OX40 receptor binds to the OX40 ligand to provide a co-stimulatory signal that is independent of CD28. Blockade of OX40-OX40 ligand interactions has been shown to ameliorate experimental EAE and inflammatory bowel disease, imply that these interactions are important in the pathogenesis of some autoimmune diseases.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: TNFRSF4